BNR — Burning Rock Biotech Share Price
- $62.59m
- -$17.62m
- CNY537.44m
- 68
- 59
- 36
- 54
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.62 | ||
Price to Tang. Book | 0.62 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 0.86 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -83.16% | ||
Return on Equity | -66.95% | ||
Operating Margin | -116.55% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | CNYm | 381.68 | 429.9 | 507.86 | 563.24 | 537.43 | 785.53 | 1,186.5 | 20.81% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Burning Rock Biotech Ltd is a holding company mainly engaged in the next generation sequencing (NGS) based cancer therapy selection. The Company operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The Company mainly conducts its businesses in the China market.
Directors
- Yansheng Han CHM (42)
- Leo Li CFO (36)
- Shaokun Chuai COO (41)
- Zhihong Zhang CTO (45)
- Hao Liu OTH (47)
- Feng Deng DRC (57)
- Gang Lu DRC
- Jing Rong DRC (39)
- Yunxia Yang DRC (47)
- Wendy Hayes IND (51)
- Min-jui Shen IND (56)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- March 10th, 2014
- Public Since
- June 12th, 2020
- No. of Employees
- 786
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
NASDAQ Global Market
- Shares in Issue
- 102,440,448
![Blurred out image of a map](https://www.stockopedia.com/assets/conversion/images/maps_placeholder.jpg)
- Address
- No. 5 Xingdao Ring Road North, GUANGZHOU, 510005
- Web
- https://www.brbiotech.com/
- Phone
- +86 18501641666
- Auditors
- Ernst & Young Hua Ming LLP
Latest News for BNR
Upcoming Events for BNR
Q2 2024 Burning Rock Biotech Ltd Earnings Release
Burning Rock Biotech Ltd Annual Shareholders Meeting
Similar to BNR
Airsculpt Technologies
NASDAQ Global Market
Biodesix
NASDAQ Global Market
Exagen
NASDAQ Global Market
Fulgent Genetics
NASDAQ Global Market
InterCure
NASDAQ Global Market
FAQ
As of Today at 23:40 UTC, shares in Burning Rock Biotech are trading at $6.11. This share price information is delayed by 15 minutes.
Shares in Burning Rock Biotech last closed at $6.11 and the price had moved by -54.74% over the past 365 days. In terms of relative price strength the Burning Rock Biotech share price has underperformed the S&P500 Index by -64.49% over the past year.
The overall consensus recommendation for Burning Rock Biotech is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreBurning Rock Biotech does not currently pay a dividend.
Burning Rock Biotech does not currently pay a dividend.
Burning Rock Biotech does not currently pay a dividend.
To buy shares in Burning Rock Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $6.11, shares in Burning Rock Biotech had a market capitalisation of $62.59m.
Here are the trading details for Burning Rock Biotech:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: BNR
Based on an overall assessment of its quality, value and momentum Burning Rock Biotech is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Burning Rock Biotech is $4.01. That is 34.39% below the last closing price of $6.11.
Analysts covering Burning Rock Biotech currently have a consensus Earnings Per Share (EPS) forecast of -CNY1.88 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Burning Rock Biotech. Over the past six months, its share price has underperformed the S&P500 Index by -36.58%.
As of the last closing price of $6.11, shares in Burning Rock Biotech were trading -23.74% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Burning Rock Biotech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $6.11.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Burning Rock Biotech's management team is headed by:
- Yansheng Han - CHM
- Leo Li - CFO
- Shaokun Chuai - COO
- Zhihong Zhang - CTO
- Hao Liu - OTH
- Feng Deng - DRC
- Gang Lu - DRC
- Jing Rong - DRC
- Yunxia Yang - DRC
- Wendy Hayes - IND
- Min-jui Shen - IND